Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for CytomX Therapeutics (CTMX) over the last 10 years, with Dec 2024 value amounting to $78.3 million.

  • CytomX Therapeutics' Shares Outstanding (Weighted Average) rose 111.11% to $164.9 million in Q3 2025 from the same period last year, while for Dec 2023 it was $67.0 million, marking a year-over-year increase of 1.37%. This contributed to the annual value of $78.3 million for FY2024, which is 16.82% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Shares Outstanding (Weighted Average) of $78.3 million as of FY2024, which was up 16.82% from $67.0 million recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $78.3 million in FY2024 and a low of $46.2 million during FY2020.
  • For the 3-year period, CytomX Therapeutics' Shares Outstanding (Weighted Average) averaged around $70.4 million, with its median value being $67.0 million (2023).
  • Data for CytomX Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 41.16% (in 2021) over the last 5 years.
  • CytomX Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $46.2 million in 2020, then soared by 41.16% to $65.2 million in 2021, then climbed by 1.28% to $66.1 million in 2022, then increased by 1.37% to $67.0 million in 2023, then climbed by 16.82% to $78.3 million in 2024.